Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia
2013
Not all patients with core binding factor acute myeloid leukemia (CBF-AML) display a good outcome. Modern risk factors include KIT and/or FLT3 gene mutations and minimal residual disease (MRD) levels, but their respective values have never been prospectively assessed. A total of 198 CBF-AML patients
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
33
References
238
Citations
NaN
KQI